Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
ROVI Rating ESG 2020
Fri, 25/09/2020 - 14:25
0 min
Download related document
Select rating
Give ROVI Rating ESG 2020 1/5
Give ROVI Rating ESG 2020 2/5
Give ROVI Rating ESG 2020 3/5
Give ROVI Rating ESG 2020 4/5
Give ROVI Rating ESG 2020 5/5
No votes yet
Related
ROVI completes the manufacture of the first batches of Moderna vaccine for EU
Laboratorios Farmacéuticos Rovi, S.A. (BME -Spanish Stock Exchanges and Markets: ROVI), a pan-European specialised company engaged in the...
2 min
13/01/2021
The Journal npj Schizophrenia Publishes the Results of the PRISMA-3 Study of...
Today, Laboratorios Farmacéuticos Rovi, S.A. (www.rovi.es) has announced the online publication of the results of the pivotal study PRISMA-...
4 min
27/11/2020
The Spanish Prime Minister, Pedro Sánchez, makes an institutional visit to ROVI...
This morning, the facility of Laboratorios Farmacéuticos ROVI, S.A. (ROVI) in San Sebastián de los Reyes (Madrid) received an...
3 min
26/11/2020
See More
Email
Facebook
Twitter
LinkedIn